For instance, ABT‐263 (navitoclax), a BCL‐2 family inhibitor, is not only senolytic to senescent cells, but also cytotoxic against platelets and neutrophils, often resulting in thrombocytopenia and neutropenia (Leverson et al., 2015). This evidence concerns the gene BCL2 and Thrombocytopenia.